LUPIN ENDS PROMOTION AGREEMENT IN U.S.

Mumbai-based Lupin's U.S. subsidiary Dec. 25 announced it ended its agreement with Chester Valley Pharmaceuticals.

The companies had, in March 2006, entered into an agreement to promote Atopiclair Nonsteroidal Cream to pediatricians in the U.S.

Both parties have now mutually agreed to end the agreement and to independently pursue their respective business plans.

Lupin has a focus on anti-TB, cephalosporins (anti-infectives) and cardiovascular drugs (prils and statins) and has a presence in the areas of diabetology, NSAIDs and Asthma.